Research Investments in Global Health: A Systematic Analysis of UK Infectious Disease Research Funding and Global Health Metrics, 1997–2013

Head, Michael G; Fitchett, Joseph R; Nageshwaran, Vaitehi; Kumari, Nina; Hayward, Andrew; Atun, Rifat

doi:10.1016/j.ebiom.2015.12.016

Cited by 30 publications

(29 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HBV has attracted far fewer resources for clinical management and research than other chronic infectious diseases such as HIV, HCV or malaria . A recent report in the UK shows that HBV receives 0.7% of total expenditures compared to 3.0% for HCV, 13.9% for malaria and 17.5% for HIV . As mentioned, mortality from HBV is now higher than that of malaria while the latter receives nearly five times more funding.…”

Section: Barriers To Hbv Treatmentmentioning

confidence: 99%

How to improve access to therapy in hepatitis B patients

Subic

Zoulim

2018

Liver International

View full text Add to dashboard Cite

Despite the availability of a preventive vaccine and active antiviral treatments that stop disease progression and reduce the risk of hepatocellular carcinoma, hepatitis B is still a major public health problem. Only an estimated 10% of the 257 million people living with HBV have been diagnosed and as few as 1% are being adequately treated. Barriers to diagnosis and treatment include: (i) limited awareness and lack of knowledge about HBV infection and HBV‐related diseases; (ii) under‐diagnosis with insufficient screening and referral to care; (iii) limited treatment due to drug availability, costs, reimbursement policies and the need for long‐term or life‐long therapy. These barriers and the actions needed to improve access to treatment are strongly influenced by the prevalence of infection and affect middle‐high vs low‐middle income countries differently, where most HBV carriers are found. In high‐prevalence regions and low‐to middle‐income countries, the main challenges are availability and cost while in low‐prevalence regions and middle‐to high‐income countries low screening rates, public awareness, social stigma and discrimination play an important role. Overcoming these challenges on a global scale is a complex clinical and public health challenge and multilateral commitment from pharmaceutical companies, governments, funders and the research community is lacking. The new WHO 2016 Global Health Sector Strategy on viral hepatitis targets testing and treatment, suggesting that important but strong actions are needed from advocacy groups, scientific societies and funding agencies to foster awareness and access to cure.

show abstract

Section: Barriers To Hbv Treatmentmentioning

confidence: 99%

How to improve access to therapy in hepatitis B patients

Subic

Zoulim

2018

Liver International

View full text Add to dashboard Cite

show abstract

“…In contrast, the funding level for cardiovascular diseases, musculoskeletal disorders, transport injuries, and self-harm and interpersonal violence was relatively low in comparison with their contributions to DALYs. Similar limited alignment of health R&D funding and disease burden has also been reported in other countries, such as the United Kingdom (UK) and India, regardless of the source of the funding and whether it is in the domestic or global context, is not necessarily consistent [5][6][7].…”

Section: Discussionmentioning

confidence: 56%

“…A similar trend is also observed in the UK and India. While the UK has a domestic DALYs distribution similar to that of Japan, Head et al (2016) identified that research investments awarded to UK institutions from public and international funders demonstrated relative research strengthens in some neglected tropical diseases in light of the global DALYs' context [6]. This indicates that neglected tropical diseases are an important area of UK's global health policy; the UK is known to be the second largest investors in global R&D for neglected tropical diseases in the world [43].…”

Section: Discussionmentioning

confidence: 99%

“…The need to align investments in health research and development (R&D) with the public health needs is one of the most important public health challenges in Japan, as in other countries and the world [1][2][3][4][5][6][7][8][9][10]. According to the data from the Organisation for Economic Cooperation and Development (OECD), Japan's R&D expenditures (in all sectors, not just the health sector) are comparable to those of OECD countries.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Limited alignment of publicly competitive disease funding with disease burden in Japan

et al. 2020

View full text Add to dashboard Cite

show abstract

“…More and more, researchers are asked to prepare a detailed budget plan, and justify the used financial resources. The funding agencies, professional organizations, investors, industries, and governments on the other hand are under pressure to be savvy with their spending and they are keen to allocate the money in the most efficient way to reach their goals (1). …”

mentioning

confidence: 99%